iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Recruiting · NCT03192501 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
What this trial is about
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
- There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
- The patient is informed consent and signed a written consent.
Exclusion criteria
- Age \> 70 or \<18 years old.
- Previous history of malignant tumors.
- Pregnant or lactating female patients.
- Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
Where it is running
1 location listed.
- The Second Affiliated Hospital of Guangzhou Medical University - Guangzhou, Guangdong, China